Navigation Links
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Date:2/9/2011

TARRYTOWN, N.Y., Feb. 9, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will webcast an investor briefing on Sunday, February 13 from 9 a.m. to 10:30 a.m. Eastern Time.  At the investor briefing, principal investigators from the VEGF Trap-Eye clinical studies will recap presentations from the Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2011 meeting being held in Miami, Florida on Saturday, February 12.  

The investigator presentations will provide additional data from the VIEW 1 and VIEW 2 Phase 3 trials in patients with the neovascular form of age-related macular degeneration (wet AMD), the COPERNICUS Phase 3 trial in macular edema due to central retinal vein occlusion (CRVO), and the DA VINCI Phase 2 trial in diabetic macular edema (DME).  Regeneron reported positive top-line results from all these trials in the fourth quarter of 2010.

"It's a privilege to be able to release this important collection of VEGF Trap-Eye data at the Bascom Palmer Eye Institute's Eighth Annual Angiogenesis Meeting," said  Philip J. Rosenfeld, M.D., Ph.D., Professor of Ophthalmology, University of Miami Miller School of Medicine and Course Co-Director of the Angiogenesis 2011 Meeting.  "In particular, the Phase 3 results in wet AMD suggest that the VEGF Trap-Eye has the potential to address an important unmet need of providing optimal vision gain while reducing the burden of intravitreal injections and office visits for patients and their caregivers."  

The webcast and slides may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page (http://investor.regeneron.com).  An archived version of the presentation will be available after the live webcast through M
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Regeneron Announces Presentation at the ISI Annual Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
3. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
4. Christine A. Poon Elected to Regeneron Board of Directors
5. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
6. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
7. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Regeneron Increases Size of Public Offering of Common Stock
9. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
10. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip.  Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... 9 Triax Pharmaceuticals, LLC announced today ... exclusive strength of tretinoin; Tretin-X 0.0375%, for the treatment ... patients that offers a between strength – ... elegant, hydrating cream vehicle. For those patients already on ...
... known as PCOS, is a silent and often mysterious disease ... risk of serious illness. PCOS is the ... of heart disease, insulin resistance, diabetes and certain cancers. It ... child bearing age, affecting 5 to 10 million women nationwide, ...
Cached Medicine Technology:New, Exclusive Strength: Tretin-X® 0.0375%(tretinoin) Cream 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 2Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers 3
(Date:5/18/2013)... Each year, the American Gastroenterological Association (AGA) ... achievements in gastroenterology through its esteemed recognition awards. ... talented individuals who work tirelessly to advance the ... pleased to announce the 2013 recognition award honorees ... their tremendous contributions to our field," said Loren ...
(Date:5/18/2013)... 18, 2013 Also known as ... popular weight loss surgery that guarantees patients long-term weight ... Center wishes to give readers a brief tutorial on ... medical school at New York City’s Mount Sinai School ... he undertook a fellowship in Minimally Invasive Bariatric Surgery. ...
(Date:5/18/2013)... Illuminations is proud to present the Inner ... will take place over the course of four days, on ... Saturday, June 8, 2013. , Inner Child Therapy is concerned ... the attitudes, patterns and coping mechanisms that create the behavior ... to live a more integrated and balanced life style, to ...
(Date:5/18/2013)... swallow high-powered magnets often need surgery and other invasive ... study. The researchers, from the Louisiana State University ... 79 percent of children who swallowed very strong "neodymium ... which a tube containing a camera is inserted into ... can be treated through observation or by pumping the ...
(Date:5/18/2013)... May 18, 2013 MOOSGO.COM published an original ... This book features a group of artists who share their ... photographs, illustrations and paintings. Exclusively for iPad . ... including songs and videos that reflect the signature idiosyncrasy and ... at the Apple iBook Store and it includes a ...
Breaking Medicine News(10 mins):Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Illuminations Brings World Renowned Therapist to the Middle East 2Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New Art Book for iPad: Tango Art 2
... the nation,s largest builder of healthcare facilities, has ... hospital for Virtua Health. Turner is serving as ... scheduled for completion in 2011. The 690,000-sq.-ft. hospital ... quality clinical services and patient safety, an assurance ...
... 30 Diagnosoft, Inc., an innovator in magnetic ... diagnosis, staging and therapeutic monitoring of cardiovascular disease, ... Strain-encoding, or SENC, is a new MRI ... contraction, or relaxation, of the heart,s myocardium. ...
... Healthcare Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... in partnership with physicians and manager of Physhield ... released the following letter to its shareholders:Dear Phyhealth ... Congress and a new administration in Washington. ...
... Study says initiatives should target both coverage and access to ... Children who do not have health insurance and no regular ... unmet medical needs, researchers at the University of Michigan C.S. ... government needs to do more to safeguard the health of ...
... (Nasdaq: BCRX ) today announced that its fourth ... on Friday, February 6, 2009. Following the release, BioCryst will ... Eastern Time to discuss the financial results and provide an ... by Jon P. Stonehouse, President and Chief Executive Officer, Stuart ...
... Neurosilicon,s novel Photoconductive Stimulation Device (PSD) was highlighted in ... Astrocytic Ca2+ Waves Guide CNS Growth Cones to Remote ... November 2008 issue of The Public Library of Science ... in mediating axonal guidance. It is known that the ...
Cached Medicine News:Health News:Turner Reaches Milestone on $323 Million Virtua West Jersey Replacement Hospital in Voorhees, N.J. 2Health News:Diagnosoft(R) Introduces Its Third MRI Analysis Innovation 2Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4Health News:Medical Needs of 6.2 Million U.S. Kids Go Unmet 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 2Health News:BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009 3Health News:Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration 2
... enclosures are designed for ... other process gas to ... HEPA filtration, heating/cooling, humidification, ... also available, along with ...
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
Medicine Products: